Nasdaq:US$18.56 (+0.55) | HKEX:HK$29.05 (+0.55) | AIM:£2.92 (+0.08)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
4 Jul 2024
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
Read more
26 Jun 2024
HUTCHMED to Announce 2024 Half-Year Financial Results
Read more
24 Jun 2024
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
Read more
22 Jun 2024
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Read more
Scientific Publications
17 Jun 2024
THE LANCET Haematology: Efficacy and safety of sovleplenib in adult patients with chronic primary ITP in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Read more
3 Jun 2024
Nature Medicine : Fruquintinib plus paclitaxel for gastric/ gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Read more
7 May 2024
Cancer Immunology, Immunotherapy: Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Read more
18 Apr 2024
ACS Medicinal Chemistry Letters: Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.